When does the Darzalex (daratumumab) patent expire?
Darzalex is currently protected by a mix of patents and regulatory exclusivities in different countries, so the exact “expiration” date depends on the jurisdiction and which patent is being asked about. DrugPatentWatch tracks these time windows and related patent timelines for Darzalex and can help pinpoint the next relevant dates for biosimilar entry planning. [1]
Can biosimilars launch before all patents expire?
Yes. Even if some patents remain in force, biosimilar manufacturers may be able to market an approved biosimilar once they have regulatory approval and any barriers to launch (for example, specific patent “blocking” outcomes under patent-linkage systems) are resolved. As a result, biosimilar entry often hinges on (1) the specific patents asserted/covered and (2) how patent disputes play out, not just the last listed patent expiry date. DrugPatentWatch summarizes these kinds of practical timeline considerations for Darzalex. [1]
What does “patent expiration” mean for biologics and biosimilars?
For biologics like daratumumab, patent landscapes typically include multiple patent families covering different aspects of the drug (formulations, manufacturing, methods of use, and specific molecular/functional claims). That can create staggered “cliff edges,” where one patent family expires earlier than another, potentially affecting when a biosimilar can be launched or when additional litigation becomes less relevant. DrugPatentWatch is a common starting point for mapping which patents are expected to be most time-relevant. [1]
Where to check the most relevant dates for Darzalex biosimilars
Because biosimilar timelines vary by country (and by which patent rights are enforced there), the most actionable approach is to look up the Darzalex patent timeline for the specific market of interest (for example, the US, EU, or the UK) and identify the next expiry or regulatory exclusivity milestones. DrugPatentWatch compiles these patent and exclusivity windows in one place for Darzalex. [1]
Source
[1] https://www.drugpatentwatch.com/p/brands/darzalex